Lifestyle During and After Cancer Treatment

Clinical Oncology

Volumn 19, Issue 8, 2007, Pages 616-627

  Thomas, R ^a   Davies, N ^a  

^a CRANFIELD UNIVERSITY   (United Kingdom)

Author keywords

Cancernet.co.uk; diet; exercise; lifestyle; progression; treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CALCIUM; CARCINOGEN; CAROTENOID; CYCLOOXYGENASE 2 INHIBITOR; FENRETINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; MEVINOLIN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOESTROGEN; PLACEBO; PLANT MEDICINAL PRODUCT; POLYPHENOL DERIVATIVE; RETINOL; SALICYLATE SODIUM; SELENIUM; SIMVASTATIN; TRACE METAL; UNINDEXED DRUG; VITAMIN D; WARFARIN; ZINC;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY COMPOSITION; BREAST CANCER; CALCIUM INTAKE; CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONSTIPATION; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG METABOLISM; EVIDENCE BASED MEDICINE; FAT INTAKE; FATIGUE; FOOD PREFERENCE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; META ANALYSIS; NONHUMAN; NUTRITIONAL COUNSELING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RECURRENT CANCER; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; WEIGHT GAIN; WELLBEING;

ANTIOXIDANTS; DIET; DISEASE PROGRESSION; EXERCISE; FATIGUE; HUMANS; LIFE STYLE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; QUALITY OF LIFE; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; VITAMINS;

EID: 34548175237     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.06.002     Document Type: Article

References (123)

1. Shimizu H., Ross R.K., Bernstein L., et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63 (1991) 963-999
2. Chan J.M., Gann P.H., and Giovannucci E.L. Role of diet in prostate cancer development and progression. J Clin Oncol 23 32 (2005) 8152-8160
3. Sonn G.A., Aronson W., and Litwin M.S. Impact of diet on prostate cancer: a review. Prostate Cancer Prostate Dis 8 (2005) 304-310
4. Wilkinson S., and Chodak G.W. Critical review of complementary therapies for prostate cancer. J Clin Oncol 21 11 (2003) 2199-2210
5. Hall N. Survival in colorectal cancer: impact of body mass and exercise. Gut 55 (2005) 8-10
6. Haydon A.M., Macinnis R.J., English D.R., et al. The effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 55 (2006) 62-67
7. Quadrilatero J., and Hoffman-Goetz L. Physical activity and colon cancer. A systematic review of potential mechanisms. J Sports Med Phys Fitness 43 (2003) 121-138
8. Friedenreich C.M., and Orenstein M.R. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 132 Suppl 11 (2002) 3456-3464
9. Thomas R., Daly M., and Perryman J. Forewarned is forearmed - randomised evaluation of a preparatory information film for cancer patients. Eur J Cancer 36 2 (2000) 52-53
10. Rorth M., Andersen C., Quist M., et al. Health benefits of a multidimensional exercise program for cancer patients undergoing chemotherapy. J Clin Oncol 8010 Suppl (2006) 731
11. Thomas R., Blades M., Williams M., and Godward S. Dietary advice combined with a salicylate, mineral and vitamin supplement (CV247) has some tumour static properties: a phase II study. Nutr Food Sci 35 6 (2005) 436-451
12. Ornish D., Weidner G., Fair W.R., et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174 (2005) 1065-1070
13. Pantuck A.J., Leppert J.T., Zomorodian N., et al. Phase II study of pomegranate juice for men with rising PSA following surgery or RXT for prostate cancer. Clin Cancer Res 12 13 (2006) 4018-4026
14. Madaan S., Abel P.D., Chaudhary K.S., et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. Int J Urol 86 (2000) 736-741
15. Baron J.A., Cole B.F., Sandler R.S., et al. A randomised trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 10 (2003) 891-899
16. Harris R.E., Namboodiri K.K., and Farrar W.B. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7 (1996) 203-205
17. Sandler R.S., Halabi S., Baron J.A., et al. A randomised trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348 10 (2003) 883-890
18. Blacklock C.J., Lawrence J.R., Wiles D., et al. Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians, and patients taking low dose aspirin. J Clin Pathol 54 (2001) 553-555
19. NCRN. NCRN portfolio (2006). www.ncrn.org.uk/portfolio
20. Kroenke C.H., Fung T.T., Hu F.B., et al. Dietary patterns and survival after breast cancer diagnosis. J Clin Oncol 23 36 (2005) 9295-9303
21. Iop A., Manfredi A.M., and Bonura S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol 15 (2004) 712-720
22. Dimeo F.C., Stieglitz R.D., Novelli-Fischer U., et al. Effects of physical exercise on the fatigue and psychological status of cancer patients during therapy. Cancer 85 (1999) 2273-2277
23. Schwartz A.L., Mori M., Gao R., et al. Exercise reduces daily fatigue in patients with breast cancer receiving chemotherapy. Med Sci Sports Exerc 33 (2001) 718-723
24. Galster H., et al. Activation of coagulation and thrombotic risk for different groups. Thromb Res 100 (2000) 381-388
25. Knols R., Aaronson N.K., Uebelhart D., et al. Physical exercise in cancer patients during and after medical treatment: a systemic review of randomised and controlled clinical trials. J Clin Oncol 23 16 (2005) 3830-3842
26. Winningham M., MacVicar M.G., Bondoc M., et al. Effect of aerobic exercise on body weight and composition in patients with breast cancer on adjuvant chemotherapy. Oncol Nurs Forum 16 (1989) 683-689
27. MacVicar M., Winningham M., and Nickel J. Effects of aerobic interval training on cancer patients' functional capacity. Nurse Res 38 (1989) 348-351
28. Kadan-Lottick N.S., Vanderwerker L.C., Block S.D., et al. Psychiatric disorders and mental health service use in patients with advanced cancer. Cancer 104 12 (2005) 2872-2881
29. Mock V., Dow K.H., Meares C., et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 24 (1997) 991-1000
30. Mock V., Pickett M., Ropka M.E., et al. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract 9 (2001) 119-127
31. Courneya K.S., Mackey J.R., Bell G.J., et al. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol 21 (2003) 1660-1668
32. McKenzie D., and Kalda A. Effect of upper extremity exercise on secondary lymphedema in breast cancer patients: a pilot study. J Clin Oncol 21 (2003) 463-466
33. Pinto B.M., Clark M.M., Maruyama N.C., et al. Psychological and fitness changes associated with exercise participation among women with breast cancer. Psychooncology 12 (2003) 118-126
34. Holmes M.D., Stampfer M.J., Colditz G.A., et al. Dietary factors and the survival of women with breast cancer. Cancer 85 5 (1999) 826-835
35. Rohan T.E., Hiller J.E., and McMichael A.J. Dietary factors and survival from breast cancer. Nutr Cancer 20 (1993) 167-177
36. Dignam J.J., et al. Effect of body mass index on outcome in patients with dukes B and C colon cancer: an analysis of NSABP trials. J Clin Oncol 3533 (2006) 254s
37. Gross M., et al. Obesity, ethnicity and surgical outcome for clinically localized prostate cancer. J Clin Oncol 5 9615 Suppl (2006) 865
38. Meyerhardt J.A., Heseltine D., Niedzwiecki D., et al. The impact of physical activity on patients with stage III colon cancer: findings from Intergroup trial CALGB 89803. Proc Am Soc Clin Oncol 24 (2005) Abstract 3534
39. Chlebowski R.T., et al. Dietary fat reduction in post menopausal women with primary breast cancer. J Clin Oncol 10 (2005) 3s
40. Gritz E.R., Carr C.R., Rapkin D., et al. Predictors of long-term smoking cessation in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 2 (1993) 261-270
41. Ostroff J.S., Jacobsen P.B., Moadel A.B., et al. Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer. Cancer 75 2 (1995) 569-576
42. Richardson G.E., Tucker M.A., Venzon D.J., et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 119 (1993) 383-390
43. Stevens M.H., Gardner J.W., Parkin J.L., et al. Head and neck cancer survival and life-style change. Arch Otolaryngol Head Neck Surg 109 11 (1983) 746-749
44. Chen L., Stacewicz-Sapuntzakis M., Duncan C., et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 93 (2001) 1872-1879
45. Giovannucci E., Rimm E.B., Liu Y., et al. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94 (2002) 391-398
46. Giovannucci E.L., et al. A prospective study of physical activity and incident of fatal prostate cancer. Arch Intern Med 165 (2005) 1005-1010
47. Stivala L.A., Savio M., Quarta S., et al. The antiproliferative effect of beta-carotene requires p21waf1/cip1 in normal human fibroblasts. J Biochem 267 (2000) 2290-2296
48. Kucuk O., Sarkar FH., Djuric Z., et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med 227 (2002) 881-885
49. Williams A.W., Boileau T.W.M., Zhou J.R., et al. Beta-carotene modulates human prostate cancer cell growth and may undergo intracellular metabolism to retinol. J Nutr 130 (2000) 728-732
50. Heinonen O.P., Albanes D., Virtamo J., et al. Prostate cancer and supplementation with alpha-tocopherol and beta carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90 (1998) 440-446
51. Omenn G.S., Goodman G.E., Thornquist M.D., et al. Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene in retinol efficacy trial. J Natl Cancer Inst 88 (1996) 1550-1559
52. Svilaas A., Sakhi A.K., Andersen L.F., et al. Intake of antioxidants in coffee, wine and vegetables are correlated with plasma carotenoids in humans. J Nutr 134 (2004) 562-567
53. Schoonen W.M., Salinas C.A., Kiemeney L.A.L.M., et al. Alcohol consumption and the risk of prostate cancer in middle-aged men. Int J Cancer 113 (2005) 133-140
54. Food and Drug Administration. Carcinogens and antioxidants, 2006.
55. Marklund S.L., Westman N.G., Lundgren E., et al. Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res 42 5 (1982) 1955-1961
56. Coombs G.F. Status of selenium in prostate cancer prevention. Br J Cancer 91 (2004) 195-199
57. Jackson M.J., et al. Are there functional consequences of a reduction in selenium intake in UK subjects?. Proc Nutr Soc 63 (2004) 513-517
58. DiSilvestro R.A. Copper activation of superoxide dismutase in rat erythrocytes. Arch Biochem Biophys 274 1 (1989) 298-303
59. Levieux A. Immunoquantitation of rat erythrocyte superoxide dismutase: its use in copper deficiency. Free Radic Biol Med 11 6 (1991) 589-595
60. Merli A., Rossi GL., Djinoviccarugo K., et al. Evidence for breaking of the active site dimetal cluster in Cu,Co superoxide dismutase upon copper reduction: a polarized absorption spectra study. Biochem Biophys Res Commun 25 (1995) 1040-1044
61. Westman N.G., and Marklund S.L. Copper- and zinc-containing superoxide dismutase and manganese-containing superoxide dismutase in human tissues and human malignant tumours. Cancer Res 41 7 (1981) 2962-2966
62. Liang J.Y., Liu Y.Y., Zou J., et al. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 40 (1999) 200-207
63. Leitzmann M.F., Stampfer MJ., Wu K., et al. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 95 (2003) 1004-1007
64. Clark L.C., et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81 (1998) 730-734
65. Costello A.J. A randomised, controlled chemoprevention trial of selenium in familial prostate cancer: rationale, recruitment, and design issues. Urology 57 Suppl 1 (2001) 182-184
66. Millier M. Enrollment begins for largest-ever prostate cancer prevention trial. J Natl Cancer Inst 93 (2001) 1132
67. Rodriguez C., Jacobs EJ., Mondul A.M., et al. Vitamin E supplements and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 378-382
68. Campbell M.J., Koeffler H.P., et al. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 89 (1997) 182-185
69. Evans B.A., Griffiths K., and Morton M.S. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147 (1995) 295-302
70. Hsieh T., and Wu J.M. Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1 alpha, 25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun 235 (1997) 539-544
71. Slawin K., Kadmon D., Park S.H., et al. Dietary fenretinide decreases the tumour incidence of ras induced carcinomas in the mouse reconstitution model system. Cancer Res 53 (1993) 4461-4465
72. Paganini-Hill A., Chao A., Ross R.K., et al. Vitamin A, beta carotene and the risk of prostate cancer. J Natl Cancer Inst 79 (1987) 443-448
73. Lee C.Y. Phytochemicals and apples. Lancet 359 12 (2002) 9301
74. Fraga C.U. Ascorbic acid protects against endogenous oxidative DNA damage in human sperm. Proc Natl Acad Sci USA 8 (1991) 11003
75. Peehl D.M., Skowronski R.J., Leung G.K., et al. Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54 (1994) 805-810
76. Schwartz G.G., Whitlatch L.W., Chen T.C., et al. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 14 (1994) 1077-1081
77. Blutt S.E., McDonnell T.J., Polek T.C., et al. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of bcl-2. Endocrinology 141 (2000) 10-17
78. Zhao X.Y., Ly L.H., Peehl D.M., et al. Induction of androgen receptor by 1 alpha, 25-dihydroxyvitaminD3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140 (1999) 1205-1212
79. Chan J.M., Stampfer M.J., Ma J., et al. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 8 (1999) 893-899
80. Lee I.M., Cook NR., Gaziano J.M., et al. Vitamin E in the primary prevention of cardiovascular disease and cancer. The Women's Health Study: a randomised controlled trial. J Am Med Assoc 294 (2005) 56-65
81. Holmes M.D., Chen W.Y., Feskanich D., et al. Physical activity and survival after breast cancer diagnosis. J Am Med Assoc 293 (2005) 2479-2486
82. Amling C., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22 (2004) 439-445
83. Chlebowski R., Aiello E., and McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 20 (2002) 1128-1143
84. Wu A., Pike M., and Stram D. Dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 91 (1999) 529-534
85. Adlercreutz H., Fotsis T., and Bannwart C. Urinary estrogen profile determination in young Finnish vegetarian and omnivorous women. J Steroid Biochem 24 (1986) 289-295
86. Rose D.P. Dietary fibre, phytoestrogens and breast cancer. Nutrition 8 (1992) 47-51
87. Keyomarsi K. Synchronization of tumour cells by Lovastatin. Cancer Res 51 (1991) 3602-3609
88. Graaf M.R., Beiderbeck A.B., Egberts A.C.G., et al. The risk of cancer in users of statin. J Clin Oncol 22 (2004) 2366-2394
89. Augustsson K., Michaud DS., Rimm E.B., et al. A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 12 (2003) 64-67
90. Terry P., Lichtenstein P., Feychting M., et al. Fatty fish consumption and risk of prostate cancer. Lancet 357 (2001) 1764-1766
91. Norrish A.E., Skeaff CM., Arribas G.L., et al. Prostate cancer risk and the consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer 81 (1999) 1238-1242
92. Terry P.D., Rohan T.E., and Wolk A. Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr 77 (2003) 532-543
93. Chaudry A.A., Wahle K.W., McClinton S., et al. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 57 (1994) 176-180
94. Hsu A.L., Ching T.T., Wang D.S., et al. The cyclooxygenases-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275 (2000) 11397-11403
95. Dieppe P., Ebrahim S., and Juni P. Lessons from the withdrawal from rofecoxib. Br Med J 329 (2004) 867-868
96. Egan K.M., Stampfer M.J., Giovannucci E., et al. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88 (1996) 988-993
97. Fuchs C., Meyerhardt J.A., Heseltine D.L., et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803. Am Soc Clin Oncol (2005) Abstract Book
98. Schreinemachers D.M., and Everson R.B. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5 (1994) 138-146
99. Mahmud S., Franco E., and Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90 (2003) 93-99
100. Hippisley-Cox J., and Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J 330 (2005) 1366-1369
101. Westerlind K.C. Physical activity and cancer prevention mechanisms. Med Sci Sports Exerc 35 (2003) 1834-1840
102. Harvei S., Bjerve K.S., Tretli S., et al. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer 71 (1997) 545-551
103. Kristal A.R., Cohen J.H., Qu P., et al. Associations of energy, fat, calcium and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 11 (2002) 719-725
104. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131 Suppl 11 (2001) 3109S-3120S
105. Kaaks R., Toniolo T., Akhmedkhanov A., et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92 (2000) 1592-1600
106. Giovannucci E., Pollak M.N., Platz E.A., et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9 (2000) 345-349
107. Ma J., Giovannucci E., Pollak M., et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96 (2004) 546-553
108. Ma J., Pollak M.N., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF binding protein-3. J Natl Cancer Inst 91 (1999) 620-625
109. Nomura A.M., Stemmermann G.N., Lee J., et al. Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol 158 (2003) 424-431
110. Palmqvist R., Hallmans G., Rinaldi S., et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 50 (2002) 642-646
111. Probst-Henson N.M., Yuan J.M., Stanczyk F.Z., et al. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 85 (2001) 1695-1699
112. Baxter R.C., and Turtle J.R. Regulation of hepatic growth hormone receptors by insulin. Biochem Biophys Res Commun 84 (1978) 350-357
113. Suikkari A.M., Koivisto V.A., Rutanen E.M., et al. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 66 (1988) 266-272
114. Yu H., and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92 (2000) 1472-1489
115. Freier S., Weiss O., Eran M., et al. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 44 (1999) 704-708
116. Warren R.S., Yuan H., Matli M.R., et al. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 271 (1996) 29483-29488
117. Giles G.G., and English D.R. The Melbourne Collaborative Cohort Study. IARC Sci Publ 156 (2002) 69-70
118. Land C.E. Studies of cancer and radiation dose among atomic bomb survivors: the example of breast cancer. J Am Med Assoc 274 5 (1995) 1-6
119. Li H. Manganese superoxide dimutase polymorphism, prediagnostic antioxidant status and risk of clinical significant prostate cancer. Cancer Res 65 (2005) 2498-2504
120. Joosten E., van den Berg A., Riezler R., et al. Metabolic evidence that deficiencies of vitamin B12, folate, and vitamin B6 occur commonly in older people. Am J Clin Nutr 58 (1992) 468-476
121. Slater T.F., Cheeseman K.H., Davies M.J., et al. Free radical mechanisms in relation to tissue injury. Proc Nutr Soc 1 (1987) 1-12
122. One To One Health Exercise and Nutrition (2006). www.healthdept.co.uk
123. Davies N.J., and Kinman G. Health baseline comparison theory: Adjustment to rheumatoid arthritis. Health Psychol Update 15 3 (2006) 31-36